XTX Topco Ltd Makes New Investment in Sana Biotechnology, Inc. (NASDAQ:SANA)

XTX Topco Ltd purchased a new position in Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 175,167 shares of the company's stock, valued at approximately $286,000. XTX Topco Ltd owned approximately 0.08% of Sana Biotechnology at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Geode Capital Management LLC lifted its stake in Sana Biotechnology by 0.8% during the fourth quarter. Geode Capital Management LLC now owns 3,193,081 shares of the company's stock valued at $5,206,000 after purchasing an additional 26,601 shares during the last quarter. Corient Private Wealth LLC boosted its stake in shares of Sana Biotechnology by 161.7% during the 4th quarter. Corient Private Wealth LLC now owns 1,182,699 shares of the company's stock worth $1,928,000 after acquiring an additional 730,699 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Sana Biotechnology by 0.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,056,512 shares of the company's stock worth $1,722,000 after acquiring an additional 8,666 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Sana Biotechnology by 3.0% during the fourth quarter. Bank of New York Mellon Corp now owns 336,828 shares of the company's stock valued at $549,000 after purchasing an additional 9,905 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Sana Biotechnology by 1,838.3% in the 4th quarter. Renaissance Technologies LLC now owns 319,818 shares of the company's stock valued at $521,000 after purchasing an additional 303,318 shares during the period. Institutional investors own 88.23% of the company's stock.

Sana Biotechnology Price Performance

Shares of NASDAQ SANA remained flat at $1.77 during trading hours on Friday. The company had a trading volume of 2,295,821 shares, compared to its average volume of 3,309,059. The firm has a market capitalization of $398.29 million, a P/E ratio of -1.26 and a beta of 1.78. The company's 50 day moving average price is $2.12 and its 200-day moving average price is $2.63. Sana Biotechnology, Inc. has a 1-year low of $1.26 and a 1-year high of $10.50.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last issued its quarterly earnings data on Monday, March 17th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.25) by $0.02. Equities research analysts anticipate that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have issued reports on the company. HC Wainwright reaffirmed a "buy" rating and set a $11.00 price objective on shares of Sana Biotechnology in a research note on Thursday. TD Cowen raised shares of Sana Biotechnology from a "hold" rating to a "buy" rating in a research note on Wednesday, January 8th. Jefferies Financial Group began coverage on Sana Biotechnology in a research report on Friday, March 14th. They issued a "buy" rating and a $7.00 target price for the company. Finally, Citizens Jmp upgraded Sana Biotechnology from a "market perform" rating to an "outperform" rating and set a $5.00 price objective for the company in a research report on Tuesday, March 18th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $10.80.

Sana Biotechnology Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.